Boehringer Ingelheim and Lilly have decided not to launch their new diabetes drug Trajenta in Germany and say the country’s new pricing controls are to blame. The companies are preparing to launch Trajenta in other European countries later this month, but came to the decision that Germany’s pricing policy would not reflect the “the positive benefits” of their medicine. Trajenta was approved by the EMA last month for use as a monotherapy in type II diabetics whose sugar levels are inadequately controlled by diet and exercise alone, and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
